These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23581534)

  • 1. Factors associated with warfarin discontinuation, including bleeding patterns, in atrial fibrillation patients.
    Suh DC; Choi JC; Schein J; Kim S; Nelson WW
    Curr Med Res Opin; 2013 Jul; 29(7):761-71. PubMed ID: 23581534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of hemorrhage and treatment costs associated with warfarin drug interactions in patients with atrial fibrillation.
    Suh DC; Nelson WW; Choi JC; Choi I
    Clin Ther; 2012 Jul; 34(7):1569-82. PubMed ID: 22717419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population.
    Deitelzweig SB; Buysman E; Pinsky B; Lacey M; Jing Y; Wiederkehr D; Graham J
    Clin Ther; 2013 Aug; 35(8):1201-10. PubMed ID: 23867114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
    Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
    Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
    Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
    Arch Intern Med; 1996 Feb; 156(4):409-16. PubMed ID: 8607726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation.
    Howard PA; Ellerbeck EF; Engelman KK; Patterson KL
    Pharmacoepidemiol Drug Saf; 2002; 11(7):569-76. PubMed ID: 12462133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Warfarin exposure and the risk of thromboembolic and major bleeding events among medicaid patients with atrial fibrillation.
    Boulanger L; Hauch O; Friedman M; Foster T; Dixon D; Wygant G; Menzin J
    Ann Pharmacother; 2006 Jun; 40(6):1024-9. PubMed ID: 16735649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice.
    Abdelhafiz AH; Wheeldon NM
    Am J Geriatr Pharmacother; 2008 Mar; 6(1):1-11. PubMed ID: 18396243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation/Interruption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation.
    Spivey CA; Qiao Y; Liu X; Mardekian J; Parker RB; Phatak H; Claflin AB; Kachroo S; Abdulsattar Y; Chakrabarti A; Wang J
    J Manag Care Spec Pharm; 2015 Jul; 21(7):596-606. PubMed ID: 26108384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Warfarin Discontinuation in Patients With Unprovoked Venous Thromboembolism: A Large US Insurance Database Analysis.
    Xie L; Liu X; Phatak H; Mardekian J; Tan W; Baser O; Ramacciotti E
    Am J Ther; 2016; 23(6):e1744-e1753. PubMed ID: 26214203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of bleeding in very old atrial fibrillation patients on warfarin: relationship with ageing and CHADS2 score.
    Poli D; Antonucci E; Marcucci R; Fatini C; Alterini B; Mannini L; Falciani M; Abbate R; Gensini GF; Prisco D
    Thromb Res; 2007; 121(3):347-52. PubMed ID: 17597186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
    DeEugenio D; Kolman L; DeCaro M; Andrel J; Chervoneva I; Duong P; Lam L; McGowan C; Lee G; DeCaro M; Ruggiero N; Singhal S; Greenspon A
    Pharmacotherapy; 2007 May; 27(5):691-6. PubMed ID: 17461704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    DiMarco JP; Flaker G; Waldo AL; Corley SD; Greene HL; Safford RE; Rosenfeld LE; Mitrani G; Nemeth M;
    Am Heart J; 2005 Apr; 149(4):650-6. PubMed ID: 15990748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anemia, hypoalbuminemia, and renal impairment as predictors of bleeding complications in patients receiving anticoagulation therapy for nonvalvular atrial fibrillation: a secondary analysis.
    Abdelhafiz AH; Myint MP; Tayek JA; Wheeldon NM
    Clin Ther; 2009 Jul; 31(7):1534-9. PubMed ID: 19695402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with atrial fibrillation: a retrospective analysis.
    Ghate SR; Biskupiak JE; Ye X; Hagan M; Kwong WJ; Fox ES; Brixner DI
    Ann Pharmacother; 2011 Jun; 45(6):701-12. PubMed ID: 21666081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
    Eikelboom JW; Wallentin L; Connolly SJ; Ezekowitz M; Healey JS; Oldgren J; Yang S; Alings M; Kaatz S; Hohnloser SH; Diener HC; Franzosi MG; Huber K; Reilly P; Varrone J; Yusuf S
    Circulation; 2011 May; 123(21):2363-72. PubMed ID: 21576658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation.
    Song X; Sander SD; Varker H; Amin A
    Am J Cardiovasc Drugs; 2012 Aug; 12(4):245-53. PubMed ID: 22775446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.